Vyteris adds four new recruits to scientific board
This article was originally published in Clinica
Transdermal drug delivery technology firm Vyteris has strengthened its scientific advisory board with four appointments. Joining the board are David Cohen, Robert Shorr, David Filer and Michael Reidy. The new board members all come from different employment backgrounds: Mr Cohen is currently vice-chairman of clinical affairs at the New York University Medical Center’s department of Dermatology; Mr Shorr has served as chief scientist at biotech firm United Therapeutics; Mr Filer is a consultant to emerging companies; and Mr Reidy is also currently vice-president, research and development at Vyteris. Fair Lawn, New Jersey-based Vyteris has developed “the first active, ready-to-use drug delivery patch to receive marketing clearance from the US FDA”. The LidoSite device is designed to deliver drugs comfortably through the skin using low-level electrical energy.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals